Fig. 3
From: DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming
The DNMT3A mutation accelerates cell cycle through NAM metabolic reprogramming. A GSEA enrichment of differential genes in the Dnmt3aR878H/WT mouse model, human AML-M5 samples with the DNMT3A R882 mutation and U937 cell lines with the DNMT3A-R882H mutation compared with the wild type. B Proliferation velocity of U937, U937MUT and U937WT cell lines. C, D The changes of cell number of the U937MUT and U937WT cell lines with the treatment of NAM. E Cell division of U937MUT cell line indicated by CFSE after NAM treatment. F Percent divided and division index of U937MUT after NAM treatment. G, H Cell cycle changes of the U937MUT cell line after NAM treatment indicated by PI (propidium iodide). I Different binding ability between CDK2-CCNE2 and CDK4-CCND3 in U937WT and U937MUT. The mean ± SD of minimum n = 3 independent experiments is displayed, representative images shown *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001 (Student’s T-test)